「them22iplmodel senju」の検索結果
100件：56～60件目を表示
-
R&D Pipeline | Research & Development | SENJU Pharmaceutica
PROGRESS OF DEVELOPMENT Disclosuring of information after Phase 1 DrugIndicationStatus (Region) SJP-0132Dry eyeApproval（Japan） PranoprofeninflammationApplication under review (Vietnam) SJP-0132Dry eye
http://www.senju.co.jp/english/rd/pipeline.html -
Meetings of the Minds | Research & Development | SENJU Pharmaceutica
ki Matsumoto2, Yoshinori Yamagiwa1, Kotaro Yamada1, Hideya Yonekura1, Gen Suzuki1, Ikuyo Atsumi1 1: Senju Pharmaceutical Co., Ltd. 2: Mochida Pharmaceutical Co., Ltd. ARVO 2025 開催日：2025年5月4日～2025年5月8日...
http://www.senju.co.jp/english/rd/society/ -
OTC Products, etc. | Products | SENJU Pharmaceutical
Inquiries are not accepted in a language other than Japanese in principle. Please kindly understand the situation that the inquiries by telephone must use Japanese only. Translated from the Japanese p
http://www.senju.co.jp/english/products/otc.html -
MytearV | OTC Products, etc. | Products | SENJU Pharmaceutical
Category 2 OTC medicines Mytear® V Resolves redness of the eye and provides healthy and clear eyes. CHARACTERISTICS Compounded with "tetrahydrozoline hydrochloride", a component to relieve r
http://www.senju.co.jp/english/products/mytearv.html -
Mytear ALPITATTO NEXα | OTC Products, etc. | Products | SENJU Pharmaceutical
This medicine is recommended for people who have continuing allergy symptoms with inflammation. Category 2 OTC medicines Mytear® ALPITATTO NEXα Works on unbearable eye itching due to pollens and other
http://www.senju.co.jp/english/products/nex.html